TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05263336
Drug: Verdye Green
Normalized name: acid green 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: intraoperative iv application of indocyanic green for visualisation of blood supply to the anastomosis after rectal cancer recection
Study: NCT05222399
Drug: LY3871801
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05177601
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral placebo during the TMS treatments (20 days).
Study: NCT05672888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Study: NCT00238160
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06314334
Drug: P-GemOx
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. pegaspargase 2000U/m\^2, capped at 3750U on day 1, intramuscular;~2. gemcitabine 1.0g/m\^2 on day 1 and day 8, intravenous drip;~3. oxaliplatin 130mg/m\^2 on day 1, intravenous drip
Study: NCT05620160
Drug: RAY1216
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAY1216（tablet）
Study: NCT05620160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo （tablet）
Study: NCT06153134
Drug: 10% Curcuma xanthorriza Roxb.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental arms will receive 10% Curcuma xanthorriza Roxb. cream for 2 months
Study: NCT05835505
Drug: BRS201
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Study: NCT05835505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Groups 1, 2, 3, and 4 will all contain 7 subjects each, with each subject receiving active study drug and placebo in a randomized order; half will receive the placebo first for four weeks followed by active treatment for four weeks, while the other half will receive active treatment for four weeks followed by placebo for four weeks.
Study: NCT04816487
Drug: Potassium Iodide or Glutathione
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive either Glutathione or Potassium iodide
Study: NCT06244004
Drug: Antiandrogen Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo SOC ADT
Study: NCT01431586
Drug: JDtic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.~Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug.
Study: NCT05126121
Drug: three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,tinidazole,metronidazol
Study: NCT06244004
Drug: Cytotoxic Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive SOC cytotoxic chemotherapy
Study: NCT06258265
Drug: TAK-279 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-279 matching placebo capsule.
Study: NCT05231694
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will receive 1ml volume of physiological saline (PS) injected into the gluteal muscle, once a day for 4 weeks.
Study: NCT06405490
Drug: Nanoliposomal Irinotecan+Oxaliplatin +Capecitabine+Cadonilimab
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Use the above medications on a regular basis
Study: NCT06449859
Drug: TQC2938 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC2938 injection is a humanized monoclonal antibody that interfering with the signal cascade.
Study: NCT06449859
Drug: TQC2938 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQC2938 Placebo is a placebo comparator
Study: NCT05696483
Drug: OLX-07010 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 and 75 mg capsules
Study: NCT05452187
Drug: Assess the effectiveness and safety of DAAs in patients with IBD.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variables evaluated: age, gender, location, extent, phenotype, and activity of IBD, treatments, anti-HCV and viral load, DAA treatment and duration, fibrosis and hepatic decompensation and adverse effects (AE).
Study: NCT05452187
Drug: Evaluate the interaction of DAAs with IBD drugs, particularly immunosuppressants and/or biologics.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Variables evaluated: Interactions.
Study: NCT04857840
Drug: Firibastat (QGC001) Period 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg (2 x 500 mg) tablets QD per Os
Study: NCT05279352
Drug: FBR-002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration on D1 and D3
Study: NCT05279352
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration on D1 and D3
Study: NCT04940741
Drug: VER-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study: NCT05135468
Drug: CU-40102 Spray
Normalized name: Cu 2+
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical application, 1\~4 sprays each time, once daily
Study: NCT05445440
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05445440
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05752175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT04884295
Drug: XVR011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of XVR011 via intravenous (IV) infusion
Study: NCT05801367
Drug: Allium Sativum Oil
Normalized name: Allium sativum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allium sativum oil will be used as non-vital pulpotomy medicament compared with Formocresol (which is gold standard)
Study: NCT05098249
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participant takes wo capsules Placebo orally three times a day over 30 days beginning the day of Ferinject administration.
Study: NCT05825365
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Transfer to selumetinib on REiNS-defined PD)
Study: NCT05000216
Drug: Continue IS (MTX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants continue to take their immunosuppressive (IS) medications for management of their autoimmune disease without alterations in schedule and dosing.
Study: NCT04969172
Drug: Exosomes overexpressing CD24
Approvals — FDA: no, EMA: no, PMDA: no
Description: The suggested therapeutic agent here is based on an existing therapeutic platform that uses exosomes that were engineered to overexpress CD24 that can directly suppress the cytokine storm. The exosomes will be isolated and purified from human embryonic kidney T-REx™-293 cells that constitutively express high levels of human CD24.
Study: NCT05474924
Drug: Prednisolone tablets
Normalized name: Prednisolone Tablets
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral prednisolone tablet dosage 1 mg/kg/d tapered daily for 2 weeks.
Study: NCT05264870
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: treatment of postspinal hypotension
Study: NCT05747664
Drug: DWP16001
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3mg
Study: NCT04441047
Drug: AlloStim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Living, activated allogeneic Th1-like memory immune cells
Study: NCT06169202
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2 orally twice daily, D1-14, repeated every 3 weeks.
Study: NCT06079788
Drug: Adrenocorticotrophic Hormone
Normalized name: Adrenocorticotrophic hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in complete remission, ACTH is given at a prednisone dose of 1.5-2mg/kg qod or 0.75-1mg/kg qd. ACTH 2 IU/kg/ day, qd,（the maximum dose ≤ 50 IU）, 28 days of continuous use for 5 days， for 24 weeks.~Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks.If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
Study: NCT06079788
Drug: Steroid
Normalized name: Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients in complete remission, Prednisone: 5mg；Oral tablets; 1.5-2 mg/kg, qod or 0.75-1mg/kg/day,qd, then gradually taper the steroid by 0.25mg/kg qod or 0.125mg/kg qd every 4 weeks. If stable, taper to 5mg qod (body surface area \> 1.0m2) and 2.5mg qod (body surface area \< 1.0m2) and maintain the dose until study completion.
Study: NCT05892614
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion over approximately 60 minutes every 4 weeks
Study: NCT05045534
Drug: Comparison of TB-840 treatment with Placebo
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose or Multiple Dose of TB-840 treatment
Study: NCT04662567
Drug: acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: compare the postoperative pain 1 hour and \~24h post surgery
Study: NCT05917912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Study: NCT05987358
Drug: TQB3454 tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3454 is a selective IDH1 mutant enzyme inhibitor.
Study: NCT05987358
Drug: TQB3454 tablets matching placebo
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets without active substance.
Study: NCT04273607
Drug: Subcutaneous Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention group will receive prophylactic heparin instead of standard of care therapeutic intravenous heparin
Study: NCT05427981
Drug: Belbuca Buccal Product
Normalized name: Belbuca Buccal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine Buccal Films
Study: NCT05970575
Drug: NE3107
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take 20mg twice daily (BID) approximately 12 hours apart. The dose will be stable the duration of the study intervention (6 months)
Study: NCT04985929
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical-grade placebo pill, over-encapsulated to be identical in appearance to the sildenafil intervention.
Study: NCT06116734
Drug: Grastofil®
Approvals — FDA: no, EMA: no, PMDA: no
Description: On day 5 after the hemopoietic stem cell transplant, one subcutaneous injection for 5 days
Study: NCT04531592
Drug: Isotonic saline solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution consisting of 0.9% sodium chloride in the volume of 300 ml for administration
Study: NCT03398252
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to receive a placebo for doxazosin XL.
Study: NCT05631405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with placebo
Study: NCT04608981
Drug: Prednisolone 30 mg
Normalized name: prednisolone 30 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroidal anti-inflammatory drug as a preoperative medication
Study: NCT04608981
Drug: Diclofenac Potassium 50mg Tab
Normalized name: DICLOFENAC POTASSIUM 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug as a preoperative medication
Study: NCT04608981
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch
Study: NCT05465668
Drug: DWP16001 Drug A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 Drug A
Study: NCT05465668
Drug: DWP16001 Drug C
Normalized name: Synovex C Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP16001 Drug C
Study: NCT05386953
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received normal saline as a maintenance crystalloid during liver transplantation surgery.
Study: NCT05386953
Drug: Balanced crystalloid solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received balanced crystalloids such as lactated Ringer's solution or Plasma solution as a maintenance crystalloid during liver transplantation surgery.
Study: NCT05242029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo in a clinical setting.
Study: NCT05914155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administer placebo IV infusion every two weeks for two doses in double-blind phase.
Study: NCT05613491
Drug: Intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put 0.9% sodium chloride into nasal special drug delivery device.Before anesthesia induction, give the first equal volume saline nasal spray, once per hour, 20 IU each time, until the end of the operation
Study: NCT04580238
Drug: Botox 200 UNT Injection
Normalized name: Botox 200 UNT Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Protocol:~Botox 200 IU vials for 40 patients for the duration of study (4 treatment cycles); Treatment will be based on the PREEMPT study full treatment (standard of care) and follow the pain protocol to a total of 195 IU in standard injection sites
Study: NCT06382649
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo by mouth once, followed by placebo by mouth every 1 hour as needed for ongoing delirium or agitation (at the discretion of the treating physician), for a maximum of three doses
Study: NCT06243198
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (SC)
Study: NCT04913610
Drug: Placebo for ABBV-4083
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT05390749
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate 3.5g/m2 civ d1/cycle5-6
Study: NCT00000703
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06206824
Drug: Leucettinib-21
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm's description.
Study: NCT00000703
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000703
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00000703
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04892641
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for 250 mg epetraborole hydrochloride tablets for oral administration
Study: NCT06547437
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline 0.9% 100 cc
Study: NCT06220188
Drug: [177Lu]Lu-PSMA I&T
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 cycles (3 GBq in first cycle and 6 GBq in the second cycle) of \[177Lu\]Lu-PSMAI\&T radioligand therapy at 6-week intervals
Study: NCT04272372
Drug: Ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PO and local therapy
Study: NCT04882124
Drug: CSJ117
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSJ117 (4 mg and 8 mg) inhaled once daily for 12 weeks. Delivered via Concept1 device.
Study: NCT04882124
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled once daily for 12 weeks. Delivered via Concept1 device
Study: NCT04999839
Drug: NDI-034858 study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDI-034858 2 mg oral capsules.
Study: NCT04999839
Drug: NDI-034858 study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDI-034858 5 mg oral capsules.
Study: NCT04999839
Drug: NDI-034858 study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDI-034858 15 mg oral capsules.
Study: NCT04999839
Drug: NDI-034858 study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NDI-034858 30 mg (2\*15 mg) oral capsules.
Study: NCT06317558
Drug: Other drugs for neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs other than immune checkpoint inhibitors are being used as a new adjuvant setting for patients with NSCLC.
Study: NCT05141344
Drug: Melatonin 3 MG Oral Tablet
Normalized name: melatonin 3 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: it will be given orally one hour preoperatively
Study: NCT05141344
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar-coated tablets will be given one hour preoperatively
Study: NCT06451302
Drug: cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses and intensity of chemotherapy vary according to risk stratification. Mainenance therapy is added to high-risk patients.
Study: NCT05664828
Drug: SN132D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manganese-based macromolecular MRI contrast agent
Study: NCT04770428
Drug: MEDI7352
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dose of MEDI7352 will be administered as two 1.5 mL injections in the abdomen. Following an overnight fast of at least 8 hours, each participant will receive a single dose of MEDI7352 on 4 occasions.
Study: NCT04770428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as two 1.5 mL injections in the abdomen. To maintain the double-blind requirements, the placebo volume administered will be equivalent to the MEDI7352 volume administered for each dosing. Following an overnight fast of at least 8 hours, each participant will receive matching placebo on 4 occasions.
Study: NCT05454410
Drug: MIJ821 Subcutaneous Injection - high dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIJ821 supplied in vials as a powder for solution for injection, to be reconstituted, and administered as a single subcutaneous injection on Day 1
Study: NCT05454410
Drug: Placebo Subcutaneous Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride solution to be administered as a single subcutaneous injection on Day 1
Study: NCT04653480
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxaliplatin or irinotecan based regimens, according to the first line treatment
Study: NCT04905836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excipient solution
Study: NCT04993430
Drug: HRS8807、SHR6390
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS8807 in combination with SHR6390
Study: NCT05106127
Drug: EG-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: A Repurposed Drug
Study: NCT05444556
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally.
Study: NCT05734703
Drug: Nutraceutical Topical
Normalized name: ZINC OXIDE 154 mg in 1 mL TOPICAL LOTION [Ultraceuticals Ultra UV Protective Daily Moisturising]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application of the topical nutraceutical to two by two inch area of skin for 90 days.
Study: NCT06118385
Drug: BEN8744
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Study: NCT06118385
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulated powder in capsule for oral administration. Supplied as filled Size 0 Swedish Orange capsule. Doses: 2mg, 10mg and 40mg.
Study: NCT05451095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05742126
Drug: HSK36273
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple continuous IV infusion ascending doses for 5 days
Study: NCT05742126
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT05742126
Drug: Heparin sodium injection
Normalized name: Heparin Sodium Injection
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching positive control
Study: NCT00258141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06430697
Drug: paracetamol administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient hospitalized in Intensive Care Unit with a continuous measurement of blood pressure with a catheter and who have an administration of paracetamol by intravenous or per os
Study: NCT05633563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intake of capsules
Study: NCT04877496
Drug: History of exposure to anti-CD20 treatment since 01/01/2010
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous treatment history of anti-CD20 treatment since 01/01/2010
Study: NCT05091073
Drug: NNC0385-0434
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will be dosed with 40 mg oral NNC0385-0434 once-daily for 10 consecutive days
Study: NCT05284136
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral prednisolone at an initial dose of 40 to 60 mg/day (or 1 mg/kg for those patients who weigh less than 40 kg), with a fixed, tapering regimen such that patients should be off steroids by the last day of week 12. Increases in steroid dose during tapering of corticosteroids is allowed but if the patient receives steroids (other than hydrocortisone for adrenal insufficiency) after week 12, he/she is in failure.